Researchers developed a decision analytic model comparing an acute care penicillin skin testing intervention to no confirmatory allergy testing scenarios. The study period was one year.
Researchers found if all MSSA bacteremia patients self-reporting a penicillin allergy received penicillin skin testing services, the cost per patient would be $12,559 and 0.73 quality-adjusted life years. Alternatively, not receiving penicillin skin testing services resulted in a cost per patient of $13,219 and 0.66 quality-adjusted life years.
Additionally, the study shows that penicillin skin testing resulted in a cost-effectiveness estimate of -$9,429 per quality-adjusted life year gained.
“Patients reporting a penicillin allergy on admission may receive sub-optimal alternative therapies to beta-lactams, such as vancomycin, for MSSA bacteremia,” study authors wrote. “This economic analysis demonstrates that inpatient penicillin skin testing services confirming penicillin allergy are cost-effective for patients with MSSA bacteremia.”
More articles on healthcare quality:
Froedtert Health to pay $360K in hazardous waste disposal settlement
How detecting false penicillin allergies helps physicians fight antibiotic resistance
Physician gave excessive pain meds to 27 patients, Ohio system says
